Summary Oxygen radicals induce cytotoxicity via a variety of mechanisms, including DNA damage, lipid peroxidation and protein oxidation. Here, we explore the use of a polyethylene glycol (PEG)-stabilised enzyme capable of producing reactive oxygen species (ROS), glucose oxidase (GO), for the purpose of harnessing the cytotoxic potential of ROS for treating solid tumours. PEG-GO (200 U), administered by two intratumoral injections 3 h apart, produced a significant growth delay in subcutaneous rat 9L gliomas as compared with control animals receiving heat-denatured PEG-GO. Rats were protected from systemic toxicity by subsequent i.v. administration of PEG-superoxide dismutase (PEG-SOD) and PEG-catalase. In vivo tumour metabolic changes, monitored using 31P magnetic resonance spectroscopy (3'P-MRS) 6 h following initial administration of PEG -GO, revealed a 96 ± 2% reduction in the ATP/P, ratio and a 0.72 ± 0.10 unit decline in intracellular pH. A 3-fold sensitisation of 9L glioma cells in vitro to hydrogen peroxide could be achieved by a 24 h preincubation with buthionine sulphoximine (BSO). This study suggests that oxidation therapy, the use of an intratumoral ROS-generating enzyme system for the treatment of solid tumours, is a promising area which warrants further exploration.
Hydrogen peroxide is produced in mammalian cells during normal metabolism by different oxidases and from either spontaneous or superoxide dismutase (SOD)-catalysed superoxide anion dismutation. Hydrogen peroxide can readily cross cellular membranes, and the most sensitive cellular target structure for hydrogen peroxide is DNA, in which single-strand breaks occur (Hoffman & Meneghini, 1979; Bradley & Erickson, 1981; Imlay et al., 1988) . This genotoxicity has been proposed to be the result of transition metal-driven Haber-Weiss reactions leading to the generation of cytotoxic hydroxyl radicals (Filho & Meneghini, 1984) . Over the past 40 years there have been many attempts to treat tumour-bearing patients or animals with preformed hydrogen peroxide (Hollcroft et al., 1952; Makino & Tanaka, 1953; Turner, 1953; Green & Westrop, 1958; Sugiura, 1958; Krementz et al., 1963; Mealey, 1965; Kaibara et al., 1971) . In these reports, hydrogen peroxide was injected directly into the solid tumour, the circulation or the peritoneal cavity of mice with malignant ascites. The results from these studies, however, were anecdotal. It was not until the early 1980s that investigators reported that hydrogen peroxide can exert a direct anti-tumour effect in vivo and thus prolong host survival (Nathan & Cohn, 1981) . In that previous study, glucose oxidase (EC 1.1.3.4) was conjugated to carboxylated latex micropheres and was found to have an anti-tumour effect both in the peritoneal cavity and when injected into the tumour bed of subcutaneously implanted P388 cells at the time of cell implantation (Nathan & Cohn, 1981) . The microspheres were at the tumour site and hydrogen peroxide generation was achieved through the following reaction: GO P-D-Glucose + 02------------> D-glucono-1,5-lactone + H202
It is known that enzymes can be stabilised in vivo by attaching PEG units to the lysine residues. Enzyme modification in this manner increases in vivo half-life from 6 min to 30-40 h, reduces the antigenicity of the native protein and inhibits proteolysis (Pyatak et al., 1980) . To our knowledge, there have been no reports demonstrating growth inhibition of a solid tumour using hydrogen peroxide or a hydrogen peroxide-generating system. The unrealised potential of this treatment was the motivating factor for this present study, in which we describe the anti-tumour effect of PEG-GO on the growth of cultured 9L glioma cells and solid s.c. 9L tumours in rats. In addition, results using 31P-MRS to examine the effects of this therapeutic approach on tumour phosphate metabolites and pH in vivo are presented.
Materials and methods
Preparation of PEG-glucose oxidase (PEG-GO) The preparation of PEG-catalase, PEG-SOD and PEG-GO was accomplished using previously reported procedures for PEG-SOD (Pyatak et al., 1980) . In brief, PEG-GO was prepared by addition of 40mg of protein (Aspergillus niger) in 10 ml of 0.1 M boric acid, pH 9.8. Activated PEG (1.0 g; Mr 5,000, Sigma, St Louis, MO, USA) was added and the mixture was stirred for 1 h. Unattached PEG was removed by five sequential dialysis steps against equivalent volumes of phosphate-buffered saline (PBS) (calcium chloride, 0.9 mM; potassium chloride 2.7 mM; potassium dihydrogen phosphate 1.5 mM; magnesium chloride 0.3 mM; sodium chloride 137.0 mM; disodium hydrogen phosphate, 7.5 mM) using an Amicon (Beverly, MA, USA) ultrafiltration chamber (model 8050) equipped with an XM-50 membrane. The Mr and activity of PEG-GO were determined by laser desorption linear time-of-flight mass spectrometry (Vestec Model VT 2000) and spectrophotometry (Michiels & Remacle, 1988) respectively. PEG-SOD and PEG-catalase were assayed for activity using standard spectrophotometric methods (Pyatak et al., 1980; Michiels & Remacle, 1988 Studies to evaluate the effects of reduced intracellular glutathione (GSH) levels on sensitivity of 9L tumour cells were done by preincubating cells for 24 h in the presence of 0.1, 0.5, 1, 2 and 5 mM buthionine sulphoximine (BSO) before exposure to increasing concentrations of hydrogen peroxide as described above. GSH levels were determined spectrophotometrically using a kit provided by Bioxytech (Marne, France).
In vivo evaluation of PEG-GO Specific pathogen-free male Fischer-344 rats were purchased from Charles River Breeding Laboratories (Wilmington, MA, USA). Rats weighed 275-300 g at the beginning of the experiment and were housed in the university laboratory animal medicine facility. All procedures were approved by the Institutional Animal Care and Use Committee. Subcutaneous gliomas were induced by injection of 1 x 106 9L glioma cells in 0.2 ml of serum-free culture medium over the right thigh muscle under halothane anaesthesia. Calliper measurements of tumour dimensions were repeated every 2 days beginning on the eighth day post cell implantation. Tumour volumes were determined using the equation: Tumour volume = 0.5 (length x width2). Rats with subcutaneous gliomas were treated 12 days after cell inoculation, at which time the mean tumour volume was approximately 0.7 cm3. PEG-GO (50 or 200 U) contained in 50 lAl of phosphate-buffered saline (PBS) was administered by an intratumoral injection. Tumours treated with 200 U of PEG-GO received a second identical injection 3 h later. Care was taken to distribute the PEG-GO as evenly as possible throughout the tumour mass. At the conclusion of the second 200 U PEG-GO injection, 10,000 U each of PEG-SOD and PEG-catalase were administered i.v. in order to protect the animals from systemic toxicity owing to the potential leakage of hydrogen peroxide and/or the PEG-GO from the tumour site into the vascular system. Control animals were treated identically except that the PEG-GO was denatured by heating at 90°C for 15 min prior to injection.
In order to determine the effects of this therapy on cellular energy state in vivo, 3'P-MR spectra were recorded on several animals before and 6 and 24h after intratumoral injection using a horizontal-bore 7T Spectroscopy Imaging Systems magnetic resonance instrument. For MRS experiments, rats were anaesthetised by an i.p. injection of a mixture containing ketamine (80-100mgkg-') and xylazine (13mgkg-').
3TP-MR spectra were recorded using a single-turn 9-mm diameter surface coil probe at 121.4 MHz using the following acquisition parameters: sweep width = ± 3,000 Hz; number of transients = 1,000; interpulse delay = 2.3 s; number of data points = 4096. 3"P-MR spectra were apodised with a 30 Hz exponential line-broadening function prior to Fourier transformation. Quantification of ATP and inorganic phosphate (Pi) resonance areas was accomplished using a spectral deconvolution routine and pH was calculated from the chemical shift of Pi relative to phosphocreatine (PCr). When the PCr resonance was absent, the water resonance from the proton spectra obtained during shimming procedures was used to calculate the position of PCr and hence pH as previously described (Madden et al., 1991) . Determination of pH values using this approach has been reported to be well within the expected accuracy of the NMR pH measurement of ± 0.05-0.1 pH units (Roberts et al., 1981) .
Statistical analysis Piecewise linear regression (Wasserman & Kutner, 1990) Figure   lb ). In the presence of 0.1 mM BSO, an inhibitor of GSH synthesis, the IC50 decreased to 22ILM hydrogen peroxide, indicating an approximate 3-fold increased sensitivity to hydrogen peroxide (Figure lb) . Cell toxicity following a 24 h incubation with 0.5, 1, 2 and 5 mM BSO was identical to that observed for 0.1 mM BSO. Spectrophotometric determination of intracellular GSH levels under these conditions revealed a decreae from 42 to 20 nmol mg-' protein with 0.1 mM BSO. At BSO concentrations of 0.5 mM or higher, GSH was not detectable.
In vivo 3"P-MRS and growth inhibitor studies Shown in Figure 2 are in vivo 3'P-MR spectra of a subcutaneous 9L glioma acquired before PEG-GO injection ( Figure 2a ) and 6 h ( Figure 2b ) and 24 h (Figure 2c ATP/Pi ratio decreased by 96 ± 2% (n = 3) and was accompanied by a 0.72 ± 0.10 (n = 3) decline in tumour pH. Shown in Figure 4 is a plot of the average 9L subcutaneous tumour volumes vs the number of days after cell implantation for the control (denatured PEG-GO) and PEG-GO-treated subcutaneous 9L gliomas. The difference in growth rates between control and treated groups beginning at day 12 is significant at P<0.001. Tumours treated with 2 x 200 U PEG-GO turned from pink to a dark-brown/black colour within approximately 4 h after initiation of the treatment, accompanied by a swelling of the tumour tissue. In contrast, no significant changes in the appearance and size of tumours injected with denatured PEG-GO were found. A swelling of the hind limb bearing the tumour mass was also seen following the treatment but disappeared 1-2 days later. Rats receiving more than approximately 100 U of PEG-GO, without infusion of the antioxidative enzymes (PEG-catalase and PEG-SOD), exhibited significant side-effects including swelling of the hind limb, lethargy and ultimately death.
Discussion
The significant delay in tumour growth demonstrates the feasibility of oxidation therapy, which we define as the use of an intratumoral ROS-generating enzyme system for the treatment of solid tumours. Previous studies using direct injections of hydrogen peroxidase into solid tumours were unsuccessful (Green & Westrop, 1958) . A study using glucose oxidase conjugated to latex microspheres did not report attempts at treating solid tumours but rather tumour cells in the peritoneal cavity and co-injection of tumour cells with the micropheres at the time of s.c. implantation (Nathan & Cohn, 1981) . However, modification of GO and PEG resulted in only a 40% reduction in activity as compared with a 90% loss of enzyme activity when conjugated to latex microspheres (Nathan & Cohn, 1981 Fischer 344 rat on day 0. PEG-glucose oxidase and heatdenatured PEG-glucose oxidase was administered intratumorally on day 12 (noted by upward pointing arrow) at two separate doses of 200 U 3 h apart. At the conclusion of the second PEG-glucose oxidase dose, 10,000 U each of PEG-catalase and PEG-SOD were administered i.v. to protect the rat from systemic oxidative stress. The difference in growth rates beginning at day 12 is significant at P< 0.001. Points, means ± s.e. (n = 6 control and n = 5 treated). 0, heat denatured PEG-glucose oxidase; 0, 2 x 200 U PEG-glucose oxidase.
In this study, 3"P-MRS was used to assess the in vivo metabolic effect of oxidation therapy since two distinct mechanisms by which hydrogen peroxide can deplete cellular ATP levels are known. The first mechanism involves activation of poly(ADP-ribose) polymerase following hydrogen peroxide-induced DNA strand breaks (Schraufstatter et al., 1986) . Activation of poly(ADP-ribose)polymerase consumes NAD+, a process that is subsequently associated with a loss of ATP levels (Ueda & Hayaishi, 1985; Berger et al., 1986; Bruchelt et al., 1991) . This second mechanism involves hydrogen peroxide inhibition of glycolysis by the inactivation of glyceraldehyde 3-phosphate dehydrogenase resulting in depletion of ATP levels (Brodie & Reed, 1987 Optimisation of this therapeutic approach will require improvements in the delivery and control of the ROS-generating enzyme system and assessment of the pathological consequences. Glucose oxidase was chosen to demonstrate the concept of oxidation therapy because it has a relatively high specific activity, is commercially available and because the substrates necessary for hydrogen peroxide production, glucose and oxygen are abundant in tissue. However, this enzyme has a fundamental disadvantage in that its activity cannot be directly controlled, necessitating administration of large doses of antioxidative enzymes (or antioxidants) in order to protect the rat from systemic toxicity. This tissue may be exacerbated in the rat because blood catalase activity in this species is only 25% of that in the human (Lorincz et al., 1948) . This disparity between species is also reflected in the fact that human blood foams in contact with hydrogen peroxide, whereas this phenomenon does not occur when hydrogen peroxide is added to rat blood. Oxygenation of rat blood does not occur, but rather the blood turns dark-brown owing to the formation of methaemoglobin. Methaemoglobin formation was observed in the present studies in treated rats that were not protected by administration of PEG-catalase and PEG-SOD.
An alternative oxidase enzyme system in which the activity of the hydrogen peroxide generating system could be manipulated by substrate availability and/or direct chemical inhibition of the enzyme would provide a significant advantage over glucose oxidase. This would reduce excessive oxidative stress on surrounding normal tissues and blood. This capability would require that the substrate is not endogenous to mammalian tissue or present in low enough concentrations as not to induce significant formation of hydrogen peroxide. A specific example of an enzyme with these properties is D-amino acid oxidase (DAAO) (EC 1.4.3.3 (Griffith, 1982) . BSO has an additional advantage of selectivity as it has been shown to reduce the GSH levels of intracranial gliomas without affecting normal brain GSH levels (Lippitz et al., 1990) . Thus, pretreatment of the host with BSO should provide an excellent method for the selective sensitisation of malignant brain tumours to oxidation therapy. Further methods for sensitising gliomas to oxidative stress include, for example, inhibition of tumour antioxidant defences or DNA repair mechanisms.
Future development of oxidation therapy will entail not only optimising the oxidase system and selective presensitisation of the tumour, but also improving methods of delivery to the tumour site. For treatment of malignant brain tumours, the disrupted blood-brain barrier should also allow an i.v.-administered PEG-oxidase system selective access to the glioma tissue. Intrathecal administration of the PEG-oxidase substrate could provide for activation of the enzyme predominantly within the tumour tissue. Progress of the therapy could be monitored using localised 3'P-MRS in vivo. There are a multitude of additional variations on how oxidation therapy could be utilised for tumour treatment. Possible delivery methods include the use of liposomes, biodegradable polymers or attachment to monoclonal antibodies (Philpott et al., 1980) . Although the type of delivery vehicle will no doubt vary depending upon the tumour type and host organ targeted, our initial promising data provide evidence that oxidation therapy is a strong candidate for tumour treatment and warrants further evaluation.
